Dr Jonathan Gee

Investment Director and Chairman of North West Fund for Biomedical Investment Committee


Jonathan is chairman of the investment committee of Spark Impact and is also responsible for SPARK Ventures’ healthcare and life sciences investments. He has over fifteen years experience working with IP driven high growth technology companies as an investor and as Chief Executive of technology exploitation companies. He presently serves on the board of 7 companies.  His investment focus covers all healthcare from drug discovery to devices and diagnostics.

Investments he led include Haemostatix, a platelet substitute company recently acquired by ErgoMed plc for £28m, Oxitec, a manufacturer of GM insects for control of dengue fever, zika virus and chikungunya, acquired by NYSE quoted Intrexon Corp for over £100m in 2015, Natural Motion, a mobile gaming company acquired by Zynga Inc for over $500m in 2014, Oxford Immunotec, which floated on NASDAQ in November 2013, and GlycArt Biotechnology, acquired by Roche for over £100m in July 2005.

Jonathan manages the Isis College Funds for Oxford University and a number of its Colleges.  Prior to joining SPARK, he was involved for over ten years in the identification and development of intellectual property as the basis for innovative new products, arising from University research.  As Chief Executive of Imperial College Innovations, he was responsible for spinning out over 30 new University start up companies, and served on the board of eight of these.

He established the first seed fund at Imperial College and ran this for its first two years. He has a background in marketing in the medical diagnostics industry where he was International Product Group Manager for Unilever’s successful OTC testing company, Unipath. He gained his management training in Unilever, which he joined following a PhD in cancer research at Oxford University.